Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
X Xu, KL Poulsen, L Wu, S Liu, T Miyata… - Signal transduction and …, 2022 - nature.com
Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …
Immunological mechanisms and therapeutic targets of fatty liver diseases
Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are the two major
types of chronic liver disease worldwide. Inflammatory processes play key roles in the …
types of chronic liver disease worldwide. Inflammatory processes play key roles in the …
Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice
Abstract 17β-hydroxysteroid dehydrogenase-13 is a hepatocyte-specific, lipid droplet-
associated protein. A common loss-of-function variant of HSD17B13 (rs72613567: TA) …
associated protein. A common loss-of-function variant of HSD17B13 (rs72613567: TA) …
Therapeutic opportunities for the treatment of NASH with genetically validated targets
The identification of genetic variants associated with fatty liver disease (FLD) from genome-
wide association studies started in 2008 when single nucleotide polymorphisms in PNPLA3 …
wide association studies started in 2008 when single nucleotide polymorphisms in PNPLA3 …
[HTML][HTML] Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis
MC Podszun, AS Alawad, S Lingala, N Morris… - Redox biology, 2020 - Elsevier
Oxidative stress (OS) in non-alcoholic fatty liver disease (NAFLD) promotes liver injury and
inflammation. Treatment with vitamin E (α-tocopherol, αT), a lipid-soluble antioxidant …
inflammation. Treatment with vitamin E (α-tocopherol, αT), a lipid-soluble antioxidant …
HSD17B13: a potential therapeutic target for NAFLD
Nonalcoholic fatty liver disease (NAFLD), especially in its inflammatory form (steatohepatitis,
NASH), is closely related to the pathogenesis of chronic liver disease. Despite substantial …
NASH), is closely related to the pathogenesis of chronic liver disease. Despite substantial …
Structural basis of lipid-droplet localization of 17-beta-hydroxysteroid dehydrogenase 13
S Liu, RF Sommese, NL Nedoma, LM Stevens… - Nature …, 2023 - nature.com
Abstract Hydroxysteroid 17-beta-dehydrogenase 13 (HSD17B13) is a hepatic lipid droplet-
associated enzyme that is upregulated in patients with non-alcoholic fatty liver disease …
associated enzyme that is upregulated in patients with non-alcoholic fatty liver disease …
the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
M Amangurbanova, DQ Huang… - Alimentary …, 2023 - Wiley Online Library
Background Non‐alcoholic fatty liver disease (NAFLD) occurs in around a quarter of the
global population and is one of the leading causes of chronic liver disease. The phenotypic …
global population and is one of the leading causes of chronic liver disease. The phenotypic …
[HTML][HTML] Mouse models of nonalcoholic fatty liver disease (NAFLD): pathomechanisms and pharmacotherapies
The prevalence of non-alcoholic fatty liver disease (NAFLD) increases year by year, and as
a consequence, NAFLD has become one of the most prevalent liver diseases worldwide …
a consequence, NAFLD has become one of the most prevalent liver diseases worldwide …
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease
MX Wang, ZG Peng - Pharmacology & Therapeutics, 2023 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) has become a worldwide epidemic and a major
public health problem, with a prevalence of approximately 25%. The pathogenesis of …
public health problem, with a prevalence of approximately 25%. The pathogenesis of …